

HPV-vaccination

for the prevention of cervical precancer

The numbers are for girls and women between 15 and 26 years of age, who have received a total of three doses of Cervarix or Gardasil vaccine and have been observed between 15 and 44 months.

	10,000 patients with a placebo vaccination	10,000 patients with a HPV-vaccination
Benefits		
How many had a moderate cell change (CIN2)?	164	2
How many had an advanced cell change (CIN3)?	70	less than 1
How many had a precancerous stage of adenocarcinoma (AIS)?	9	less than 1
Harms		
How many suffered from minor side effects at the injection site (swelling, redness, pain, etc.)?	6,847	8,080
How many suffered from severe side effects (severe infections, inflammations, and other non-lethal complications)	about 669 in each group	

Short summary: In case of contact with the respective HP viruses, the HPV vaccine can protect against cell changes and precancerous stages of cervical cancer. Vaccination-related redness, swelling or pain at the injection site are possible, but severe reactions are very rare. Permanent harms and deaths caused by the vaccination are not known.

Sources: Arbyn et al. Cochrane Database Syst Rev 2018;5:CD009069.